Skip to content

Solid Biosciences

US · SLDB #3476 by market cap Listed 2018
6.85 -0.07 -1.01%
Live - 5344 symbols - heartbeat 202s ago · 2026-10-08 09:04
Pre-market 6.73 -1.75%
After-hours 6.85 0.00%
Overnight 6.87 +0.29%
Market cap
734.49M
P/B
1.96
EPS
-1.99
Reader sentiment Are you bullish or bearish on SLDB?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 1.96 Expensive vs history 77th percentile
5-year average 1.35 · #212 of 513 in Biotechnology
P/E ratio -3.62 Cheap vs history 9th percentile
5-year average -1.74 · forward -3.16
P/S ratio 119.06 Expensive vs history 92nd percentile
5-year average 44.60 · #292 of 387 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Solid Biosciences (SLDB) 734.49M -3.62 1.96 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value9.29 Economic moatNone UncertaintyVery High

Trading 35.6% below Morningstar's fair value estimate.

Fair value

Solid Biosciences Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 26% discount to our quantitative fair value estimate of $9.29 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 0.5 lies in the bottom 10% compared with peers globally. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. We believe this is a sign that shares could be cheap.

The company's balance sheet is an additional encouraging factor. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 13.8, a core component of leverage, sits in the top 10% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 09:04:36 · For reference only, not investment advice and not tailored to your situation.